|Day Low/High||128.16 / 129.45|
|52 Wk Low/High||121.00 / 148.99|
We are providing buy price levels for nearly every position in the AAP portfolio.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Jim Cramer says Netflix just went from being an easy-money stock to a hard-money stock. Investors need to know the difference.
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
It's a stock picker's market as action in individual stocks is better than on the indexes.
It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.
The Dow ends down after reaching an intraday day Tuesday as President Trump says the U.S. and China have `a long way to go' before reaching a trade agreement.
We think JNJ's valuation is still cheap as it has a below market multiple despite consistent earnings growth.
Jim shares his thoughts on earnings from JPMorgan Chase, Goldman Sachs and Johnson & Johnson.
A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #18 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #263 spot.
Johnson & Johnson posted stronger-than-expected second quarter earnings Tuesday and boosted its full-year sales outlook as international pharmaceutical revenues offset a domestic pullback.
For those trading the FANG or FAANG names, and especially Facebook, Tuesday sets up as a day bearing exceptional levels of headline risk.
The bulls will say this is healthy consolidation that will set up another leg higher, while the bears will say this is an indication of indecision and is a prelude to a rollover.
- Sales of $20.6 billion reflecting a decline of 1.3%, operational growth of 1.6%* and adjusted operational growth of 3.7%*
Here are my five rules for handling earnings season.
Buy Johnson & Johnson at its monthly and quarterly pivots at $134.76 and $135.44. These levels have been magnets following Friday's share price plunge on baby powder probe.
Here's what Jim Cramer is watching in the markets as Wall Street heads into another earnings season.
Jim discusses the market set up into second quarter earnings, Citigroup's earnings release from this morning, and much more!
Shares of Teva Pharmaceuticals fall after the company receives a downgrade from Morgan Stanley amid heightened "litigation risks" related to its involvement in the opioid crisis.
Markets surge to new records as Fed Chairman Jerome Powell signals rate cuts are likely.
News of a federal probe into whether J&J intentionally misled the public over the safety of its iconic baby powder overshadows the pharma giant's announcement of a potential HIV vaccine breakthrough.
Jim discusses Nvidia and the opportunity it has with ray-tracing technology, Apple, our healthcare stocks, and much more!
Earnings season is about to start, and the early outlook isn't good. However, there are companies out there with good prospects and we take a look at three of them.
Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.
The stock has been bouncing off the 200-day moving average line.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.